bpc 157 ulcerative colitis study JPP No 5/2013 article 09 Frontiers | Stable Gastric Pentadecapeptide

8 , e787

HGH Fragment 176-191 Research# The fragment has been studied primarily as AOD-9604 (an analog with improved stability): Preclinical models : Demonstrated selective fat loss in obese rodent models with 2-3 fold increases in fat oxidation, reduction in adiposity, and glycemic neutrality Phase 2 clinical trial : AOD-9604 was tested in obese adults but did not demonstrate statistically significant weight loss compared to placebo in the primary endpoint analysis Mechanism studies : In vitro data confirm ACC inhibition, HSL activation, and absence of GHR binding Oral formulation : Some studies have explored oral delivery of AOD-9604, representing a departure from the injectable route typical of peptide therapeutics The clinical evidence base is significantly thinner than that of full-length GH, and no regulatory approvals have been granted for the injectable peptide fragment in any major market

SLU-PP-332 250mcg x 100ct Summary Description: SLU-PP-332 is a synthetic pan estrogen receptor-related receptor (ERR?/?/?) agonist optimized for high potency toward ERR